Correlation Between Eyepoint Pharmaceuticals and Emergent Biosolutions

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eyepoint Pharmaceuticals and Emergent Biosolutions at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eyepoint Pharmaceuticals and Emergent Biosolutions into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eyepoint Pharmaceuticals and Emergent Biosolutions, you can compare the effects of market volatilities on Eyepoint Pharmaceuticals and Emergent Biosolutions and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eyepoint Pharmaceuticals with a short position of Emergent Biosolutions. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eyepoint Pharmaceuticals and Emergent Biosolutions.

Diversification Opportunities for Eyepoint Pharmaceuticals and Emergent Biosolutions

0.49
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Eyepoint and Emergent is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Eyepoint Pharmaceuticals and Emergent Biosolutions in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Emergent Biosolutions and Eyepoint Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eyepoint Pharmaceuticals are associated (or correlated) with Emergent Biosolutions. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Emergent Biosolutions has no effect on the direction of Eyepoint Pharmaceuticals i.e., Eyepoint Pharmaceuticals and Emergent Biosolutions go up and down completely randomly.

Pair Corralation between Eyepoint Pharmaceuticals and Emergent Biosolutions

Given the investment horizon of 90 days Eyepoint Pharmaceuticals is expected to under-perform the Emergent Biosolutions. But the stock apears to be less risky and, when comparing its historical volatility, Eyepoint Pharmaceuticals is 1.08 times less risky than Emergent Biosolutions. The stock trades about -0.02 of its potential returns per unit of risk. The Emergent Biosolutions is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  690.00  in Emergent Biosolutions on September 18, 2024 and sell it today you would earn a total of  197.00  from holding Emergent Biosolutions or generate 28.55% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Eyepoint Pharmaceuticals  vs.  Emergent Biosolutions

 Performance 
       Timeline  
Eyepoint Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eyepoint Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Eyepoint Pharmaceuticals is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.
Emergent Biosolutions 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Emergent Biosolutions are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent fundamental drivers, Emergent Biosolutions unveiled solid returns over the last few months and may actually be approaching a breakup point.

Eyepoint Pharmaceuticals and Emergent Biosolutions Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eyepoint Pharmaceuticals and Emergent Biosolutions

The main advantage of trading using opposite Eyepoint Pharmaceuticals and Emergent Biosolutions positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eyepoint Pharmaceuticals position performs unexpectedly, Emergent Biosolutions can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will offset losses from the drop in Emergent Biosolutions' long position.
The idea behind Eyepoint Pharmaceuticals and Emergent Biosolutions pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Other Complementary Tools

Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Directory
Find actively traded commodities issued by global exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Equity Valuation
Check real value of public entities based on technical and fundamental data